1
|
Lu Y, Yang H, Cao Y, Wang Y, Wu M, He B, Xu J, Su Z, Luo W, Liu Y, Hu W. A survival model for prognostic prediction based on ferroptosis-associated genes and the association with immune infiltration in lung squamous cell carcinoma. PLoS One 2023; 18:e0282888. [PMID: 36928232 PMCID: PMC10019706 DOI: 10.1371/journal.pone.0282888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Accepted: 02/25/2023] [Indexed: 03/18/2023] Open
Abstract
Lung squamous cell carcinoma (LUSC) is the primary pathological type of lung cancer with a less favorable prognosis. This study attempts to construct a ferroptosis-associated signature associated with overall survival (OS) that can predict the prognosis of LUSC and explore its relationship with immune infiltration. A 5 ferroptosis-associated gene model was constructed by LASSO-penalized regression analysis to predict the prognosis of patients with LUSC in the TCGA database and validated in the GEO and TCGA databases. Patients were stratified into high-risk and low-risk groups by the median value of the risk scores, and the former prognosis was significantly worse (P<0.001). Additionally, we found a certain association between the two risk groups and immune infiltration through CIBERSORT. Meanwhile, the differentially expressed genes (DEGs) between normal and tumor tissue were used to perform functional analysis, which showed a significant association with leukocyte transendothelial migration pathways in the TCGA cohort. In addition, immune cell infiltration analysis confirmed that M2 macrophages were significantly highly expressed in the high-risk group. Overall, the model successfully established by ferroptosis-associated genes suggests that ferroptosis may be related to immune infiltration in LUSC.
Collapse
Affiliation(s)
- Yanyi Lu
- Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China
| | - Hua Yang
- Department of pathology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China
| | - Yunliang Cao
- Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China
| | - Yunan Wang
- Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China
| | - Mengjia Wu
- Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China
| | - Bo He
- Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China
| | - Junzhu Xu
- Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China
| | - Zixuan Su
- Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China
| | - Wen Luo
- Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China
| | - Yuyang Liu
- Department of pathology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China
| | - Wei Hu
- Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China
- * E-mail:
| |
Collapse
|